Cargando…

Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis

BACKGROUND: Anti-cyclic citrullinated peptides (anti-CCP) are highly specific diagnostic and prognostic markers for rheumatoid arthritis (RA). They have been also found in psoriatic arthritis (PsA), with controversies as regards clinical and radiological associations. The current study assessed anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdel Fattah, Nermeen SA, Hassan, Hanan E, Galal, Zenab A, El Okda, El Sayed E
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2666753/
https://www.ncbi.nlm.nih.gov/pubmed/19298673
http://dx.doi.org/10.1186/1756-0500-2-44
_version_ 1782166073977602048
author Abdel Fattah, Nermeen SA
Hassan, Hanan E
Galal, Zenab A
El Okda, El Sayed E
author_facet Abdel Fattah, Nermeen SA
Hassan, Hanan E
Galal, Zenab A
El Okda, El Sayed E
author_sort Abdel Fattah, Nermeen SA
collection PubMed
description BACKGROUND: Anti-cyclic citrullinated peptides (anti-CCP) are highly specific diagnostic and prognostic markers for rheumatoid arthritis (RA). They have been also found in psoriatic arthritis (PsA), with controversies as regards clinical and radiological associations. The current study assessed anti-CCP in PsA and determined its clinical and radiological associations. METHODS: Four groups contributed to this study. 40 PsA, 40 psoriasis without arthritis, 40 RA and 40 healthy controls. They were tested for anti-CCP. Clinical and radiological data were collected and statistically compared between anti-CCP-positive and -negative PsA patients. RESULTS: Seven PsA (17.5%) and 34 RA (85%) were seropositive for anti-CCP. Patients of other groups were anti-CCP-negative. Regarding anti-CCP concentrations, highly significant difference existed between different groups and between anti-CCP-positive and -negative PsA. Significantly higher numbers of involved, swollen and tender joints, deformities and functional impairment of peripheral joints and radiological changes were found in anti-CCP-positive PsA. CONCLUSION: Anti-CCP may be found in PsA and are associated with higher number of involved, swollen and tender joints, with deformities and functional impairment of peripheral joints and with erosive arthritis.
format Text
id pubmed-2666753
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-26667532009-04-08 Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis Abdel Fattah, Nermeen SA Hassan, Hanan E Galal, Zenab A El Okda, El Sayed E BMC Res Notes Short Report BACKGROUND: Anti-cyclic citrullinated peptides (anti-CCP) are highly specific diagnostic and prognostic markers for rheumatoid arthritis (RA). They have been also found in psoriatic arthritis (PsA), with controversies as regards clinical and radiological associations. The current study assessed anti-CCP in PsA and determined its clinical and radiological associations. METHODS: Four groups contributed to this study. 40 PsA, 40 psoriasis without arthritis, 40 RA and 40 healthy controls. They were tested for anti-CCP. Clinical and radiological data were collected and statistically compared between anti-CCP-positive and -negative PsA patients. RESULTS: Seven PsA (17.5%) and 34 RA (85%) were seropositive for anti-CCP. Patients of other groups were anti-CCP-negative. Regarding anti-CCP concentrations, highly significant difference existed between different groups and between anti-CCP-positive and -negative PsA. Significantly higher numbers of involved, swollen and tender joints, deformities and functional impairment of peripheral joints and radiological changes were found in anti-CCP-positive PsA. CONCLUSION: Anti-CCP may be found in PsA and are associated with higher number of involved, swollen and tender joints, with deformities and functional impairment of peripheral joints and with erosive arthritis. BioMed Central 2009-03-19 /pmc/articles/PMC2666753/ /pubmed/19298673 http://dx.doi.org/10.1186/1756-0500-2-44 Text en Copyright © 2009 Abdel Fattah et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Report
Abdel Fattah, Nermeen SA
Hassan, Hanan E
Galal, Zenab A
El Okda, El Sayed E
Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis
title Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis
title_full Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis
title_fullStr Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis
title_full_unstemmed Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis
title_short Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis
title_sort assessment of anti-cyclic citrullinated peptide in psoriatic arthritis
topic Short Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2666753/
https://www.ncbi.nlm.nih.gov/pubmed/19298673
http://dx.doi.org/10.1186/1756-0500-2-44
work_keys_str_mv AT abdelfattahnermeensa assessmentofanticycliccitrullinatedpeptideinpsoriaticarthritis
AT hassanhanane assessmentofanticycliccitrullinatedpeptideinpsoriaticarthritis
AT galalzenaba assessmentofanticycliccitrullinatedpeptideinpsoriaticarthritis
AT elokdaelsayede assessmentofanticycliccitrullinatedpeptideinpsoriaticarthritis